Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis

Association pour la Recherche Clinique et Immunologique300 enrolled

Overview

Anti-carbamylated protein (anti-CarP) antibodies are present in approximately one-fourth of the patients who are seronegative for both rheumatoid factor and anti-citrullinated protein antibody and who may therefore have psoriatic arthritis. The investigators hypothesized that detection of anti-CarP antibodies in serum may be useful for diagnosis of psoriatic arthritis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

300

Conditions

Psoriasis Arthritis, Psoriatic

Interventions

Serum anti-CarP antibodies detectionDIAGNOSTIC_TEST

Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * "Controls" : Patients with a psoriasis confirmed by a dermatologist and with absence of psoriatic arthritis confirmed by a rheumatologist. * "Cases" : Patients with psoriatic arthritis fulfilling the classification criteria for psoriatic arthritis (CASPAR), with a diagnosis confirmed by a rheumatologist and associated with personal or familial psoriasis. Exclusion Criteria: * "Controls": Presence of any chronic rheumatic inflammatory disease such as psoriatic arthritis.

Locations (1)

Centre Hospitalier Lyon Sud

Pierre-Bénite, France

Outcomes

Primary Outcomes

Sensitivity of anti-carbamylated protein antibodies for the diagnosis of psoriatic arthritis in the psoriatic population

Time frame: Anti-CarP antibodies will be assessed in the sera collected at the recruitment visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.